On Friday, Shares of Adobe Systems Incorporated (NASDAQ:ADBE), gained 0.62% to $79.40.
Adobe Systems Incorporated, declared that it has received Federal Risk and Authorization Management Program (FedRAMP) Authority to Operate, a rigorous cloud security assessment for vendors that sell to the federal government. FedRAMP represents the future of digital government by providing a standardized, secure process of selecting cloud service providers that can be used across government agencies. The authorization for Adobe is sponsored by the Department of Health and Human Services.
With this certification, Adobe is the first FedRAMP cloud service provider to deliver web content management, electronic forms with eSignatures, web-conferencing, eLearning, and document rights management, as verified by an independent third-party assessment organization. These services are delivered in a hybrid cloud architecture with Software as a Service (SaaS) capabilities from Adobe Experience Manager and Adobe Connect.
Through this authorization, Adobe offers cloud security standards that are continuously delivered with ongoing updates and enhancements. Government now has access to the services that will increase operational efficiencies, reduce costs and respond faster to citizen, warfighter, or employee needs. These Adobe solutions enable government agencies to create outstanding customer experiences and become more efficient while securing mission-critical content across all devices.
Adobe Systems Incorporated is a diversified software company worldwide. It operates in three segments: Digital Media, Digital Marketing, and Print and Publishing. The Digital Media segment provides tools and solutions that enable individuals, small and medium businesses, and enterprises to create, publish, promote, and monetize their digital content.
Shares of Danaher Corporation (NYSE:DHR), declined -0.46% to $88.06, during its last trading session.
S&P Dow Jones Indices will make the following changes to the S&P 500:
Activision Blizzard, was replaced Pall Corp. (PLL) in the S&P 500 after the close of trading on Friday, August 28. S&P 500 constituent Danaher Corp. (DHR) is acquiring Pall in a transaction expected to be completed on or about that date pending final approvals.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company’s Test & Measurement segment provides test, measurement, and monitoring products that are used in electronic design, manufacturing, and technology development; hardware and software solutions to deploy, manage, and secure communication network technologies and services; and tools, toolboxes, and automotive maintenance equipment.
At the end of Friday’s trade, Shares of The Medicines Company (NASDAQ:MDCO), gained 5.95% to $33.64.
The Medicines Company today announced it will present results of recent clinical studies from its cardiovascular product portfolio at the 2015 European Society of Cardiology (ESC) Congress in London, August 29 to September 2.
The presentations at ESC 2015 will include a poster presentation of the Phase 1 results for ALN-PCSsc, a subcutaneously administered investigational RNAi therapeutic targeting PCSK9 being developed for the treatment of hypercholesterolemia. Alnylam Pharmaceuticals conducted this trial under a collaboration agreement with The Medicines Company and will present the results on Sunday, August 30 at 8:30 am British Standard Time (BST) (3:30 am Eastern Daylight Time (EDT)).
Several posters and presentations focusing on The Medicines Company’s novel intravenous antiplatelet agent, Kengreal/Kengrexal (cangrelor) as well as the company’s direct thrombin inhibitor, Angiomax/Angiox (bivalirudin), will also be presented during the meeting.
The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria; Orbactiv for the treatment of acute bacterial skin and skin structure infections; PreveLeak, a mechanical vascular and surgical sealant; ready-to-use formulation of Argatroban for the treatment of thrombosis; and Recothrom, a human recombinant thrombin used as an aid to hemostasis, as well as acute care generic products for acute cardiovascular, surgery and perioperative care, and serious infectious diseases.
Finally, Citizens Financial Group Inc (NYSE:CFG), ended its last trade with 0.80% gain, and closed at $24.67.
Citizens Bank declared that Simon Griffiths has been named Executive Vice President and Head of Retail Distribution. Griffiths, a financial services veteran with nearly 20 years of leadership experience, joins Citizens from Santander and formerly worked in senior leadership roles at JPMorgan Chase and Washington Mutual.
Griffiths will be responsible for managing Citizens’ network of branches and ATMs, online and mobile banking, digital sales and marketing and related Consumer Banking operations effective Oct. 13, 2015. He will report to Brad Conner, Vice Chairman and Head of Consumer Banking.
Citizens Financial Group, Inc. operates as the bank holding company for Citizens Bank, N.A. and Citizens Bank of Pennsylvania that provide retail and commercial banking products and services in the United States. It operates through two segments, Consumer Banking and Commercial Banking.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
